Create personalized user journeys with Omnichannel Marketing as a Service.
Empower your marketing operations with AI and Data.
Adopt a future-proof holistic approach to content strategy.
Leverage a suite of professional services for pharma and life sciences.
Develop and enable adaptable pharma and life sciences marketing content.
Enable format-free marketing with content management platform.
The innovation-powered content management platform to produce and distribute high quality digital content
Discover our story, values, and how we're making a positive impact
Explore the heart of our organization and meet the visionary minds
The Viseven team is about respect, diversity, comfortable working conditions, and equal opportunities for everyone. We explore, evolve, and adapt – together.
The pharma industry is on the cusp of a digital revolution, and Pharma 4.0 is leading the charge. With the global Pharma 4.0 market expected to reach $62.7 billion by 2032, this game-changing concept is set to transform the way drugs are discovered, developed, manufactured, marketed, and delivered.
But implementing Pharma 4.0 isn’t a simple task. It requires a comprehensive strategy, a culture of innovation, and a willingness to embrace change. In this article, we’ll explore what Pharma 4.0 entails, the key technologies driving its adoption, and the steps your company can take to successfully implement it in 2024 and beyond.
The Pharma 4.0 definition lies in the transformative adoption of Industry 4.0 principles and cutting-edge digital technologies within the pharmaceutical industry. It represents a paradigm shift towards intelligent, interconnected, and data-driven pharmaceutical manufacturing processes.
At its core, Pharma 4.0 leverages technologies such as artificial intelligence (AI), machine learning, the Internet of Things (IoT), cloud computing, and big data analytics to enhance efficiency, quality, compliance, and end-to-end visibility across the entire pharmaceutical value chain.
To understand the industrial revolutions’ impact on pharma and life sciences industries, let’s explore the past.
The first industrial revolution (1760 to 1830) was characterized by the transition from manual production methods to machines powered by water and steam. This first industrial revolution didn’t have any instant influence on pharma, but it planted the seeds of the future revolution.
The second industrial revolution (late 1800s and early 1900s) was marked by the introduction of electricity and the assembly line which enabled mass production. For pharma, it was a period of advancement, as Pfizer was established in 1849, Bayer in 1863, and Lilly in 1876. Pfizer supplied medicine for the Union during the war, Bayer commercialized aspirin, and Lilly focused on R&D and manufacturing. In the late 18th century, Switzerland swiftly developed pharma, as textile and dye manufacturers realized that their products had antiseptic properties.
The third industrial revolution (late 20th century) was driven by the advent of computers, automation, and electronics, leading to a more automated and programmable manufacturing process. This period in pharma saw the introduction of many familiar institutions and the mass production of essential technologies. Particle counters became widely available, computers facilitated research and information sharing, and communication technology enabled unprecedented global collaboration.
The fourth industrial revolution, or Industry 4.0, refers to the ongoing transformation of traditional manufacturing and industrial practices through the integration of advanced digital technologies in business processes, like IoT, AI, cloud computing, augmented reality, big data and analytics, advanced robotics, additive manufacturing (3D printing), and cyber-physical systems. These technologies make their way into the pharmaceutical industry, driving digital transformation and creating Pharma 4.0.
So, what key needs guide companies on the way to Pharma 4.0?
Pharma is strictly regulated, so it faces rigorous scrutiny when implementing changes that influence production and related aspects, creating a need for a reliable pharmaceutical quality system. Pharmaceutical manufacturers, vendors, and professionals have already begun exploring viable applications of Industry 4.0 within their organizations, while the International Society for Pharmaceutical Engineering (ISPE) is working towards better defining the various aspects that characterize Pharma 4.0.
While this solution is still far from being fully realized, and the current progress is likely just the first steps in a lengthy journey with an uncertain final destination, the ISPE European Pharma 4.0 Conference emphasized several key messages that guide along this path.
Automation alone will not be the sole transformative element in Industry 4.0 programs. Several other key factors, such as quality and holistic control strategy, workforce, efficiency, integration, and collaboration, will play a fundamental role in shaping the pharma smart factories of the future.
The term “value supply chain” highlights the need for companies to proactively collaborate with partners in an integrated supply chain, creating a system where information, raw materials, and products flow freely. Machine and equipment vendors must take an active role in building these streamlined systems.
While technological innovations in the form of new equipment, software, and services are necessary for a meaningful Industry 4.0 implementation, existing data sets should not be discarded. Advanced analysis techniques can be applied to existing data to provide useful, production-relevant insights. In this context, data integrity also becomes a major concern for the pharma businesses.
Industry 4.0 will involve not only innovation and technological breakthroughs but also improvements that allow pharmaceutical manufacturers to incorporate specific features into machines, software, or processes at their point of creation.
Although Industry 4.0 may seem focused on machines, integration, methodologies, and processes, it is ultimately based on the most powerful asset any company could have: its workforce. The human factor is a key success driver, as the objective is not to replace humans with machines but to allow humans to work on value-added activities where their creativity and problem-solving capabilities can be fully utilized.
Believing in the upsides of Industry 4.0 is essential to find the next steps and see them through to implementation. Being disruptive can allow for finding new and radical solutions to long-standing problems.
Pharma is embracing these Industry 4.0 technologies and messages across the entire value chain, from drug discovery to manufacturing, quality control, supply chain management, and regulatory compliance. This pharma digitalization promises to usher in a new era of intelligent, connected, and data-driven pharmaceutical operations, where personalized medicine, agility, and operational excellence reign supreme.
Overall, Pharma 4.0 offers pharmaceutical companies the opportunity to transform their operations, enhance product quality and safety, improve efficiency, and meet the evolving needs of patients and regulatory bodies, ultimately driving innovation and long-term business success. But let’s discuss the advantages one by one.
By leveraging technologies like automation, robotics, IoT, and cyber-physical systems, pharma companies can streamline and optimize their manufacturing processes, leading to higher productivity, reduced downtime, and lower operational costs.
Advanced technologies like real-time monitoring, process analytics, and AI-driven quality control systems can help ensure consistent product quality, reduce deviations, and minimize the risk of batch failures or product recalls.
Incorporating technologies like blockchain, IoT sensors, and digital twins can provide full visibility and traceability throughout the pharmaceutical supply chain, improving logistics, reducing counterfeiting risks, and enabling better inventory management.
By leveraging advanced modeling, simulation, and additive manufacturing (3D printing) technologies, pharma companies can accelerate the drug development process, reduce time-to-market for new products, and respond more quickly to market demands.
Additive manufacturing (3D printing) and modular production facilities enabled by Pharma 4.0 can facilitate the production of personalized medicines and small batches tailored to individual patient needs, supporting the growing trend of personalized medicine.
Pharma 4.0 technologies, such as IoT, data analytics, and blockchain, can enhance data integrity, traceability, and transparency, helping companies meet evolving regulatory requirements and maintain compliance throughout the product lifecycle.
Digital maturity is a key facilitator of the Pharma 4.0 operating model. Industrie 4.0 Maturity Index outlines six phases of digital maturity, from computerization to adaptability.
Companies at the maximum level of digital maturity will be self-adapting, capable of enduring tumultuous economic periods and fast-shifting corporate objectives to capitalize on opportunities.
The first stage of digital maturity involves automating simple manual tasks with digital technologies. The idea is to identify repetitive operations done better by computers, laying the groundwork for a digital infrastructure.
Data silos emerge due to information technology, operation technology, and communication systems being out of sync with one another, To allow employees to complete their job efficiently, you need to integrate the systems so that data flows smoothly.
At this stage of digital maturity, many companies can begin seeing gradual improvements. The interconnectivity between people, machines, and processes generates a comprehensive digital footprint of production activities. This wealth of data can be leveraged to fuel real-time, data-driven decision-making.
As more data is collected, it unveils new insights into intricate systems that were previously obscured. Advanced analytics open up opportunities for optimization and improvement across various domains.
At this stage, detailed production records allow companies to predict and rectify issues before they occur.
Systems foresee problems and automatically take appropriate action. At its most evolved, these systems are self-correcting and autonomous.
The pharmaceutical industry’s future looks to be a fully digitalized and interconnected manufacturing landscape. Smart factories use modern technologies to connect all aspects of the manufacturing process. This enables real-time optimization, predictive maintenance, and autonomous decision-making capabilities. These factories have the potential to anticipate and address possible issues before they occur by leveraging IoT sensors, advanced analytics, and machine learning algorithms. This results in reduced downtime and uninterrupted production. Moreover, the integration of cyber-physical systems enables virtual simulations and rapid prototyping, improving manufacturing processes.
The increased need for personalized medicine has resulted in a trend toward modular and flexible production methods. Additive manufacturing and modular production facilities enable the development of personalized medicine and small batches that are suited to particular patient requirements. Additive manufacturing enables the development of complicated drug delivery systems and tailored dosage forms, whereas modular facilities allow for the rapid reconfiguration of manufacturing lines for diverse pharmaceutical product types and batch sizes. This paves the path for mass customization and patient-centric manufacturing, which will revolutionize pharmaceutical production and delivery.
However, while the benefits of Pharma 4.0 are substantial, its implementation is not without challenges.
Legacy systems, data integrity concerns, regulatory hurdles, and resistance to change can act as barriers to the successful adoption of Pharma 4.0 technologies.
To overcome these challenges, pharma companies must develop comprehensive strategies that address data governance, cybersecurity measures, and regulatory compliance. Partnering with digital technology providers and regulatory bodies can help navigate the complexities of implementing Pharma 4.0 solutions while ensuring compliance with industry standards. It’s also paramount to maintain effective communication between all stakeholders, including executives, managers, vendors, pharmaceutical MSLs, and HCPs to ensure alignment and address concerns early.
Fostering a culture of innovation and change management is crucial to facilitate the successful integration of these technologies. By embracing Pharma 4.0 and its accompanying best practices, pharmaceutical companies can unlock new levels of efficiency, quality, and innovation in the manufacturing of life-saving drugs.
The pharmaceutical value chain doesn’t stop with the manufacturing process. The goal is to deliver the pharmaceutical products to the final consumer — patients. To successfully achieve that, it’s not enough just to produce drugs without any other communication with your customers. That’s why investing time and resources in marketing is equally crucial as in other areas. Pharma 4.0 technologies and tools can help you optimize your marketing processes whether you’re promoting Rx or OTC products, and enhance communication with your target audience. Let’s learn how Viseven’s eWizard platform introduces Pharma 4.0 technologies into your marketing.
eWizard is a content experience platform tailored for pharmaceutical marketing that enables companies to plan, create, collaborate on, distribute, manage, and integrate digital content at scale. The platform is powered with AI features that simplify content management and empower businesses to create personalized and relevant content while complying with MLR rules. Here’s a breakdown of eWizard’s AI-driven features.
MLR acceleration engine can speed up time-to-market by predicting the likelihood of content approval and alerting content creators when revisions are required. The solution also lets users upload emails and eDetailers for error analysis that can detect context mismatches and skipped references.
AI algorithms play a crucial role in content creation and approval processes. They not only identify incorrect or non-compliant content pieces but also provide valuable suggestions on how content creators can rectify these issues, thereby increasing the chances of approval on the initial submission. Users have access to a set of rules and corresponding comments for assets that have not been approved. Leveraging these comments, content creators can adjust their messaging, streamlining the overall content approval process.
You can leverage auto-tagging to create highly personalized and compliant marketing campaigns that resonate with your target audience. AI software allows to automatically categorize and organize structured and unstructured digital content. The system utilizes computer vision to tag audio and video content, and natural language processing to tag text files.
With these tags and the organized databases that store them, pharmaceutical companies can gain valuable insights into the performance of their content modules across various channels. This data-driven approach allows them to identify the most engaging content pieces that truly connect with their target audience, facilitating more effective and targeted marketing efforts.
Thanks to the auto-tagging functionality and a wide array of tags, your assets are enhanced with additional contextual metadata, enabling smart search. With smart search you can find the needed content pieces in a matter of seconds, even if you handle vast amounts of data (which is usually the case for pharma), streamlining content production.
eWizard enables users to produce compelling AI-simulated speaker presentations. Our clients can create content by selecting and animating an avatar that looks like a person giving a presentation. eWizard’s avatars look like actual humans, with realistic facial expressions. The solution also includes several languages and voice samples for additional customization. Companies can dramatically boost healthcare professionals’ engagement by using avatar presentations without investing considerable costs in production.
The future of pharma hinges on the successful implementation of Pharma 4.0. Companies that embrace this transformation will gain a significant competitive edge, driving efficiency, quality, and innovation in medicine development and delivery.
However, Pharma 4.0 is more than just a technology transformation; it necessitates a culture of constant adaptation, collaboration, and investment in workforce upskilling. Those who grab this opportunity, cultivate an innovative culture, and develop a comprehensive Pharma 4.0 strategy will be in a strong position to impact the future of healthcare and provide tailored, precise medicines to patients globally. The time to act is now, and the rewards for those who successfully navigate this digital transformation will be immense.
